Navigation Links
Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers

Results presented today at American College of Gastroenterology's Annual Meeting

COLLEGE PARK, Md., Oct. 16 /PRNewswire-USNewswire/ -- A clinical trial conducted by University of Maryland School of Medicine researchers and CSA Medical Inc. may yield a breakthrough treatment for pre-cancerous and cancerous diseases of the esophagus.

Results of the trial, supported by the Maryland Industrial Partnerships Program (MIPS), show that a technique called CryoSpray Ablation (TM) (CSA) can reduce and often eliminate pre-cancerous and cancerous lesions in patients, including those with Barrett's esophagus, a precursor to cancer involving esophageal lesions created by chronic acid reflux.

Trial results will be presented today at the American College of Gastroenterology's Annual Scientific Meeting in Philadelphia by Bruce Greenwald, M.D., associate professor of medicine at the University of Maryland School of Medicine, who was principal investigator of the study. The trial was conducted at the University of Maryland Medical Center in Baltimore.

"Esophageal cancer is as lethal as lung cancer and is one of the fastest growing cancers in the Western world right now," says Tim Askew, president and CEO of CSA Medical. "More than 6 million people in the U.S. have Barrett's esophagus, while 65 million people suffer from GastroEsophageal Reflux Disease (GERD), also called "acid reflux" or "heartburn". Approximately 350,000 persons with GERD develop more dangerous lesions, while 15,000 develop cancer annually, according to Askew.

CSA Medical's CryoSpray Ablation (TM) platform sprays liquid nitrogen on pre-cancerous or cancerous tissue, freezing and killing the malignant cells. Malignant cells die and slough off harmlessly, while normal tissue grows back.

"Most patients don't feel any significant pain and say it is a non-event," says Askew. "One patient said that finding parking was more difficult than the procedure. No other therapy for this type of cancer allows tissue to grow back naturally without the potential for scarring," Askew added.

Current treatments can be invasive, can require a hospital stay, and may produce severe side effects, including pain and a narrowing of the esophagus. CryoSpray Ablation (TM) is an outpatient procedure, with patients generally resuming normal activities the same or next day.

MIPS funding enabled CSA Medical to team with Dr. Greenwald in a clinical trial at the University of Maryland Medical Center. While MIPS projects typically last one year, CSA Medical's was so successful that the company stopped the trial within nine months and decided to pursue an expanded, multi-center trial.

In the past 18 months, CSA Medical has grown from one to 16 employees, raised $12 million in financing, acquired FDA clearance for its product, obtained certification to market its product in Europe, began a national, 20-center clinical trial, and commercially launched its CryoSpray Ablation (TM) product.

"The MIPS funding allowed us to validate our early clinical trial data in a major university hospital with a prominent physician," said Askew. "It was also a catalyst for our commercialization process."

More than 60 physicians around the country have been trained on CryoSpray Ablation (TM), while 16 leading hospitals are currently treating patients using the device. CSA Medical plans to add about 30 additional treatment centers in the next six months.

"I think CryoSpray Ablation will gain a firm foothold in gastroenterology for the destruction of cancer and precancerous lesions in the GI tract," says Dr. Greenwald. "It holds a unique position in its ability to treat non-flat lesions that other technologies are lacking."

CSA Medical plans to investigate CryoSpray Ablation (TM) for treating other diseases.

About MIPS (

The MTECH Maryland Industrial Partnerships Program, an initiative of the A. James Clark School of Engineering's Maryland Technology Enterprise Institute, brings university innovation to the commercial sector by supporting university-based research projects to help Maryland companies develop technology-based products.

About CSA Medical (

CSA Medical Inc. is a privately held medical technology company dedicated to pioneering CryoSpray Ablation of pre-cancerous and cancerous lesions in the gastrointestinal tract. The company's mission is to design, develop and distribute a highly versatile platform of affordable CryoSpray Ablation (CSA(TM)) products that are considered safe and effective by patients, providers and payers, worldwide.

About the University of Maryland School of Medicine (

Established in 1807, the University of Maryland School of Medicine is the fifth oldest - and first public - medical school in the nation. The School of Medicine is dedicated to providing excellence in biomedical education, basic and clinical research, quality patient care and service.

CONTACT: Eric Schurr


SOURCE Maryland Technology Enterprise Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
10. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
(Date:11/30/2015)... 30, 2015   Nuance Communications, Inc. (NASDAQ: ... Support Company (NDSC) today jointly announced a new ... that utilize the American College of Radiology,s (ACR) Imaging ... to comply with current and emerging value-based payment ... --> By combining clinical decision support, radiology reporting ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting a ... for a child’s exposure limits. , The original Nov 2015 CR story titled, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, a ... Radiology Society of North America (RSNA) annual meeting, being held November 29 – ... 2014. Throughout 2015, the company has completed installations for Integrated Delivery Network ...
(Date:11/30/2015)... , ... November 30, 2015 , ... It’s inevitable that ... family member, close friend, or animal pass away, death lives among us. It is ... , Coming from a family of 11 children, author T Sky understands that she ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... ... 2015 , ... Scott Newman MD, FACS of New York’s ... surgeons in the New York City area to utilize the new, non-invasive SculpSure™ ... laser treatment for fat loss in the abdomen, flanks, and other areas that ...
Breaking Medicine News(10 mins):